Scientific exchange · Dr. Chloé Ivanova

18 Apr 2026 · Virtual · Dr. Chloé Ivanova, Hospital Clínic Barcelona · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0177—

Capture insight from this engagement

Location: Hospital Clínic Barcelona
Therapeutic area: Neurology
Country: Spain
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Drug interactions
Dosing in hepatic impairment
Switching between CGRP agents

Scientific content used

LMV persistence data summary
CGRP class review

Questions raised

What is the persistence rate at 18 months in real-world cohorts?

Notes

Scientific exchange with headache specialist at Hospital Clínic Barcelona. Discussed drug interactions, dosing in hepatic impairment, switching between cgrp agents.

Insights captured (1)

Capture insight

INS-0062Medium
Drug interactions
Drug interactions: practice variation observed reported by headache specialist (ES).
Action in progress

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 4
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0177

Audit history (0)

All create, update and approval events for this record

No audit events in sample data